O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.
Bipolar disorder
  Rajeev Krishnadas
   Clinical Lecturer
   Sackler Institute
 University of Glasgow
Outline
•   Intro/History
•   Symptomatology and diagnosis
•   Etiopathogenesis
•   Course
•   Treatment
    – NICE
    – ...
Bipolar Disorder
 • Common illness affecting 2% of the world
   population (5% if one includes spectrum
   disorders)
 • L...
History – terms for MRCPsych
Symptomatology and Diagnosis
Symptom dimensions in Mood/Psychosis
Classification of Mood Disorders
                  Unipolar
                  single episode

                  Unipolar
‘...
Symptomatology - Mania
•   Persistently elevated, expansive, or irritable mood, lasting at least 1 week

•   Three (or mor...
Symptomatology – Hypomanic episode
•   Same symptomatology as mania
•   Duration – 4 days
•   Change noticeable by others
...
Symptomatology – Mixed episode
• The criteria are met both for a manic episode and
  for a major depressive episode (excep...
Symptomatology - Depression




                                                                              Medicating m...
Algorithm for diagnosis
Summary of DSM-IV-TR
            Classification of Bipolar Disorders

                                                    ...
Bipolar spectrum – Akiskal
Etiopathogenesis!!!!
Genetics of Bipolar disorder
•    Population risk – 1 – 2%
•    MZ concordance – 40 -45%
•    Heritability – 80 – 85%
•   ...
Approximate lifetime rates of mood disorder in various classes of
                  relative of bipolar probands



    De...
Genetics
• Strongly genetic
             – Heritability estimates approach 0.9
             – Concordance in MZ twins of 5...
Genetics of Bipolar vs Schizophrenia




                   Owen, M. J. et al. Schizophr Bull 2007 0:sbm053v1-1; doi:10.10...
Environmental factors

• Early life stress
   – Intrauterine, childhood abuse or neglect

• Recent (or chronic) life adver...
Imaging findings
• The most consistently and frequently observed findings
   – Increased white matter hyperintensities
   ...
Imaging findings
• Structural magnetic resonance imaging (MRI)
    – Abnormalities of prefrontal cortical areas (SGPFC), s...
Circuits implicated




            S M Strakowski et al. Molecular Psychiatry 2005
HPA axis abnormalities
Bipolar disorder: neuropsychology –
               endophenotypes??
• Cognitive impairment is a core feature of the disord...
Bipolar neuropsychology (1)


• Bipolar depression:       • Hypomania and mania:


• Impaired:                 • Impaired:...
Cognitive deficits in euthymic bipolar
• Large effect sizes (d≥0.8)
   – executive function (category fluency, mental mani...
Neuropsychological function in Schizophrenia vs
              Bipolar disorder




                    Schretlen, D.J., et...
Neurochemistry

• Monoamine hypothesis (The usual suspects)
  –   Serotonin
  –   Norepinephrine
  –   Dopamine
  –   Glut...
Causal pathways implicated
Secondary mood disorders
            Medical disorders
Mania               Depression
Secondary mood disorders
                 Drugs
Mania               Depression
Comorbidity
Course
• Age of onset - between 15 and 19 years
• Mostly starts with depressive episode
• Many depressives are hidden bipo...
Course
Course
•   Inter-episodic duration shortens over time
•   Progressive shortening of cycle length
•   Average of 10 episode...
Risk of relapse
NICE Guidelines

     2006
Treatment
• Acute phase
• Maintenance phase
Treat the acute phase
Consider an antipsychotic if:
 • manic symptoms are severe
 • there is marked behavioural disturbanc...
Initiate long-term
          pharmacological treatment

After a manic episode with significant risk and adverse
consequenc...
Choose long-term drugs
Base choice of lithium, olanzapine or valproate* on:

  • previous response
  • risk and precipitan...
Try alternatives if needed
If continuing symptoms or relapse, use alternative
monotherapy or add second prophylactic agent...
Support long-term
              pharmacological treatment
Ensure prescribing advisers are aware of NICE
guidance, and what...
Modify treatment for
                            rapid cycling
For an acute episode base treatment on that for manic
and d...
Use antidepressants with care

Acute manic phase

Stop antidepressants at onset of acute manic phase and
decide if discont...
Consider need for treatment


Is long-term antidepressant treatment needed after an
acute depressive episode?

No evidence...
Educate staff and service users

Raise awareness of effective antidepressant prescribing

Highlight the importance of a th...
Consider psychological therapy

For those who are stable, individual structured
psychological therapy should include:

  •...
Implement psychological
                                therapy
Offer individual structured psychological therapy

Identif...
Take possible pregnancy
                           into account
Valproate should not be used routinely for women who
may b...
Provide care for women of
                  child-bearing potential
Review care pathways and management of bipolar
disorde...
Mitigate drug-related
                              weight gain
Review medication strategy and consider:

 • dietary advic...
Support patients in
                            controlling weight
Review risk of weight gain when prescribing, offer earl...
Review annually

Over the course of the year an annual review
should include:

•   lipid levels, including cholesterol, in...
Establish review systems

Agree responsibility locally

Establish monitoring and early warning systems

Develop systems fo...
Lithium – Gold standard
Efficacy of lithium – all relapse




Geddes J, Burgess S, Hawton K, Jamison K, Goodwin G. American Journal of Psychiatry ...
Efficacy of lithium – Mania




Geddes J, Burgess S, Hawton K, Jamison K, Goodwin G. American Journal of Psychiatry 2004 2...
Efficacy of Lithium – Depression?




  Geddes J, Burgess S, Hawton K, Jamison K, Goodwin G. American Journal of Psychiatr...
Lithium - summary
• Mania – Acute treatment
   – Strong evidence in the treatment of moderate to severe manic
     episode...
Lithium – Responder signature
• Essential features
   – Recurrent mood disorder
   – Episodic course of illness
   – Remis...
Metabolic effects of Lithium




Lithium: a review of its metabolic adverse effects
Callum Livingstone and Hagen Rampes
Jo...
Monitoring – Lithium (ISBD)
     • Baseline
              – Thyroid stimulating hormone
              – Serum calcium
    ...
Anticonvulsants - MS
• Valproate, (divalproex)
   – strong evidence - effectiveness in mania,
   – moderately strong eviden...
Monitoring – Anticonvulsants (ISBD)
• Baseline
   – Valproate and carbamazepine: check for history of haematological or he...
Antipsychotics
• Typical antipsychotics,
    – Haloperidol - clear evidence on the efficacy of on the treatment of
      a...
Monitoring – Antipsychotics (ISBD)

• Baseline
   – Inquire about personal or family history of cardiac
     problems, inc...
First-line recommendations for acute
           bipolar depression




                                       Medicating m...
Bipolar depression




Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Malhi, Gin; Adams, Da...
Bipolar depression
• Partitioning treatment into acute and maintenance
  therapy is difficult based on the paucity of curren...
Efficacy of pharmacological agents as phase-specific treatments in bipolar disorder based
on available evidence




      ...
Psychological therapies




Lam DH, Burbeck R, Wright K, Pilling S. Psychological therapies in bipolar disorder: the effect...
MCQ 1
The proportion of patients that develop a depressive episode and then go on to

   develop an episode of mania withi...
MCQ 1
•   Ans B
•   In community studies, one in ten patients who begin with a depressive episode go on to develop an
    ...
MCQ 2
Which of the following is true with regard to longitudinal course of bipolar

   disorder?

    a. The duration of m...
MCQ 2
•   Ans. C
•   In any patient with bipolar disorder, the duration of individual mood episodes
    tends to be relati...
MCQ 3
Polyuria can be a troublesome side effect with lithium therapy. Which of the

   following is NOT correct with respo...
MCQ 3
• Ans . C
• Lithium related polyuria and polydipsia are seen in nearly one-third
  of those treated. Polyuria is usu...
MCQ 4
Compared to general population, the risk of Ebstein’s anomaly in children of

   mothers exposed to lithium during t...
MCQ 4
• Ans : B
• The risk of major congenital anomalies in children exposed
  to lithium in uterus is 4-12%. This is near...
MCQ 5
1. Which of the following predicts good prophylactic effect of lithium in bipolar

   disorder?

    a. Absence of f...
MCQ 5
• Ans: D
• Various clinical, biological and genetic factors that predict lithium
  responsiveness in prophylaxis of ...
Further reading

– Goodwin and Jamison’s book
– Bipolar disorders journal (2009 Suppliment)
– New Oxford Textbook of Psych...
Fin
Bipolar disorder mrcpsych
Próximos SlideShares
Carregando em…5
×

Bipolar disorder mrcpsych

5.830 visualizações

Publicada em

Bipolar disorders lecture for MRCPsych - Glasgow

Publicada em: Saúde e medicina
  • DOWNLOAD THAT BOOKS INTO AVAILABLE FORMAT (2019 Update) ......................................................................................................................... ......................................................................................................................... Download Full PDF EBOOK here { http://bit.ly/2m6jJ5M } ......................................................................................................................... Download Full EPUB Ebook here { http://bit.ly/2m6jJ5M } ......................................................................................................................... Download Full doc Ebook here { http://bit.ly/2m6jJ5M } ......................................................................................................................... Download PDF EBOOK here { http://bit.ly/2m6jJ5M } ......................................................................................................................... Download EPUB Ebook here { http://bit.ly/2m6jJ5M } ......................................................................................................................... Download doc Ebook here { http://bit.ly/2m6jJ5M } ......................................................................................................................... ......................................................................................................................... ................................................................................................................................... eBook is an electronic version of a traditional print book that can be read by using a personal computer or by using an eBook reader. (An eBook reader can be a software application for use on a computer such as Microsoft's free Reader application, or a book-sized computer that is used solely as a reading device such as Nuvomedia's Rocket eBook.) Users can purchase an eBook on diskette or CD, but the most popular method of getting an eBook is to purchase a downloadable file of the eBook (or other reading material) from a Web site (such as Barnes and Noble) to be read from the user's computer or reading device. Generally, an eBook can be downloaded in five minutes or less ......................................................................................................................... .............. Browse by Genre Available eBooks .............................................................................................................................. Art, Biography, Business, Chick Lit, Children's, Christian, Classics, Comics, Contemporary, Cookbooks, Manga, Memoir, Music, Mystery, Non Fiction, Paranormal, Philosophy, Poetry, Psychology, Religion, Romance, Science, Science Fiction, Self Help, Suspense, Spirituality, Sports, Thriller, Travel, Young Adult, Crime, Ebooks, Fantasy, Fiction, Graphic Novels, Historical Fiction, History, Horror, Humor And Comedy, ......................................................................................................................... ......................................................................................................................... .....BEST SELLER FOR EBOOK RECOMMEND............................................................. ......................................................................................................................... Blowout: Corrupted Democracy, Rogue State Russia, and the Richest, Most Destructive Industry on Earth,-- The Ride of a Lifetime: Lessons Learned from 15 Years as CEO of the Walt Disney Company,-- Call Sign Chaos: Learning to Lead,-- StrengthsFinder 2.0,-- Stillness Is the Key,-- She Said: Breaking the Sexual Harassment Story That Helped Ignite a Movement,-- Atomic Habits: An Easy & Proven Way to Build Good Habits & Break Bad Ones,-- Everything Is Figureoutable,-- What It Takes: Lessons in the Pursuit of Excellence,-- Rich Dad Poor Dad: What the Rich Teach Their Kids About Money That the Poor and Middle Class Do Not!,-- The Total Money Makeover: Classic Edition: A Proven Plan for Financial Fitness,-- Shut Up and Listen!: Hard Business Truths that Will Help You Succeed, ......................................................................................................................... .........................................................................................................................
       Responder 
    Tem certeza que deseja  Sim  Não
    Insira sua mensagem aqui

Bipolar disorder mrcpsych

  1. 1. Bipolar disorder Rajeev Krishnadas Clinical Lecturer Sackler Institute University of Glasgow
  2. 2. Outline • Intro/History • Symptomatology and diagnosis • Etiopathogenesis • Course • Treatment – NICE – Individual more recent evidence • Post lecture test !!!!!
  3. 3. Bipolar Disorder • Common illness affecting 2% of the world population (5% if one includes spectrum disorders) • Lifetime prevalence – 1% • 6th leading cause of medical disability in the developed nations • Bipolar I – equal in males and females • Bipolar II – more in females 1Cookson J. Br J Psychiatry. 2001;178(suppl. 41): s148–s156. 2Strakowski SM, et al. Expert Opin. Pharmacother. 2003;4:751-760.
  4. 4. History – terms for MRCPsych
  5. 5. Symptomatology and Diagnosis
  6. 6. Symptom dimensions in Mood/Psychosis
  7. 7. Classification of Mood Disorders Unipolar single episode Unipolar ‘Unipolar’ recurrent Dysthymia Bipolar I ‘Bipolar’ Bipolar II Cyclothymia
  8. 8. Symptomatology - Mania • Persistently elevated, expansive, or irritable mood, lasting at least 1 week • Three (or more) of the following symptoms (4/9 in ICD) – inflated self-esteem or grandiosity – decreased need for sleep (e.g., feels rested after only 3 hours of sleep) – Pressure of speech – flight of ideas or subjective experience that thoughts are racing – distractibility – increase in goal-directed activity or psychomotor agitation – excessive involvement in pleasurable activities that have a high potential for painful consequences • Marked impairment in occupational functioning or in usual social activities or relationships with others, or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features. • Exclude other causes
  9. 9. Symptomatology – Hypomanic episode • Same symptomatology as mania • Duration – 4 days • Change noticeable by others • No significant socio-occupational disturbance • No Hospitalisation • No psychotic symptoms
  10. 10. Symptomatology – Mixed episode • The criteria are met both for a manic episode and for a major depressive episode (except for duration) nearly every day during at least a 1- week period. • Socio - occupational deterioration • The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication, or other treatment) or a general medical condition (e.g., hyperthyroidism).
  11. 11. Symptomatology - Depression Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Malhi, Gin; Adams, Danielle; Berk, Michael Bipolar Disorders. 11 Sup 2:55-76, June 2009. DOI: 10.1111/j.1399-5618.2009.00711.x Copyright © 2009 Blackwell Publishing Ltd. Published by Munksgaard International Publishers Ltd. 2
  12. 12. Algorithm for diagnosis
  13. 13. Summary of DSM-IV-TR Classification of Bipolar Disorders Bipolar Disorder Bipolar I Bipolar II Cyclothymic Not Otherwise Specified One or more One or more At least 2 years of Bipolar features manic or mixed major depressive numerous periods that do not meet episodes, usually episodes of hypomanic and criteria for any accompanied by accompanied depressive specific bipolar major depressive by at least one symptoms* disorders episodes hypomanic episode MALE=FEMALE FEMALE>MALE * Symptoms do not meet criteria for manic and depressive episodes. First, ed. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Rev. Washington, DC: American Psychiatric Association; 2000:345-428.
  14. 14. Bipolar spectrum – Akiskal
  15. 15. Etiopathogenesis!!!!
  16. 16. Genetics of Bipolar disorder • Population risk – 1 – 2% • MZ concordance – 40 -45% • Heritability – 80 – 85% • Leading linked regions – 6q, 8q, 13q, 22q • Leading candidate genes – BDNF – DAOA – DISC – TPH2 – SLC6A$ • Genes implicated by GWAS – DGKH – CACNA1C – ANK3 J.H. Barnetta, J.W. Smolle. The genetics of bipolar disorder. Neuroscience. Volume 164, Issue 1, 24 November 2009, Pages 331-343
  17. 17. Approximate lifetime rates of mood disorder in various classes of relative of bipolar probands Degree of relationship Risk of bipolar disorder (Additional) risk of to bipolar proband (%) unipolar depression (%) Monozygotic co-twin 40-70 15-25 First degree relative 5-10 10-20 General population (ie, 0.5-1.5 5-10 unrelated) Owen M. et alJournal of Medical Genetics 1999;36:585-594
  18. 18. Genetics • Strongly genetic – Heritability estimates approach 0.9 – Concordance in MZ twins of 50-70% – Early-onset bipolar disorder may be even more genetic • Multiple genes confer risk (polygenic model) – similar to schizophrenia • Most recent – Family history of bipolar confers high risk for development o schizophrenia and vice versa (Lancet 2009) • Complex gene-environment interactions exist – similar to schizophrenia
  19. 19. Genetics of Bipolar vs Schizophrenia Owen, M. J. et al. Schizophr Bull 2007 0:sbm053v1-1; doi:10.1093/schbul/sbm053 Copyright restrictions may apply.
  20. 20. Environmental factors • Early life stress – Intrauterine, childhood abuse or neglect • Recent (or chronic) life adversity • Substance misuse – Alcohol; cannabis • Psychosocial deprivation
  21. 21. Imaging findings • The most consistently and frequently observed findings – Increased white matter hyperintensities – Cortical abnormalities – Amygdala, SGPrefrontal cortex, Striatum – Cerebellar structural abnormalities – Mild sulcal prominence and ventricular enlargement – Decreased activity of the D/V prefrontal cortex, when subjects are depressed – Hypo/hyperfrontality (SGPFC) when subjects are manic • No specific unifying pathophysiologic mechanism • Medications and drug use could account for some abnormalities
  22. 22. Imaging findings • Structural magnetic resonance imaging (MRI) – Abnormalities of prefrontal cortical areas (SGPFC), striatum and amygdala exist early in the course of illness - trait – Abnormalities of cerebellar vermis, lateral ventricles and other prefrontal regions (eg, left inferior), appear to develop with repeated affective episodes, and may represent the effects of illness progression and associated factors - state • Magnetic resonance spectroscopy (MRS) – Abnormalities of membrane and second messenger metabolism, in striatum and prefrontal cortex. • Functional imaging studies (fMRI) – Activation differences between bipolar and healthy controls in these same anterior limibic regions. • Dysfunction within prefrontal networks and the associated limbic modulating regions (amygdala, midline cerebellum). • Diminished prefrontal modulation of subcortical and medial temporal structures within the anterior limbic network (eg, amygdala, anterior striatum and thalamus) that results in dysregulation of mood
  23. 23. Circuits implicated S M Strakowski et al. Molecular Psychiatry 2005
  24. 24. HPA axis abnormalities
  25. 25. Bipolar disorder: neuropsychology – endophenotypes?? • Cognitive impairment is a core feature of the disorder (during depression and mania) • Cognitive impairment persists on clinical recovery: – Not simply the result of medications of previous ‘scarring’ effects of past mood episodes – Seen in unmedicated patients, first degree relatives and high risk individuals – Heterogeneity among studies
  26. 26. Bipolar neuropsychology (1) • Bipolar depression: • Hypomania and mania: • Impaired: • Impaired: – Attention (errors of – Attention (errors of omission) commission) – Verbal memory – Verbal memory – Executive function – Executive function
  27. 27. Cognitive deficits in euthymic bipolar • Large effect sizes (d≥0.8) – executive function (category fluency, mental manipulation) – and verbal learning. • Medium effect sizes (0.5≤db0.8) – immediate and delayed verbal memory – abstraction and set-shifting – sustained attention – response inhibition – psychomotor speed. • Small effect sizes (0.2≤d b0.5) – verbal fluency by letter – immediate memory – sustained attention Robinson L et al Journal of Affective disorder - 2006
  28. 28. Neuropsychological function in Schizophrenia vs Bipolar disorder Schretlen, D.J., et al. Biological Psychiatry. 2007; 62(2): 179–186
  29. 29. Neurochemistry • Monoamine hypothesis (The usual suspects) – Serotonin – Norepinephrine – Dopamine – Glutamate • Kindling hypothesis – Multiple sub-threshold stimuli – Mood stabilisers
  30. 30. Causal pathways implicated
  31. 31. Secondary mood disorders Medical disorders Mania Depression
  32. 32. Secondary mood disorders Drugs Mania Depression
  33. 33. Comorbidity
  34. 34. Course • Age of onset - between 15 and 19 years • Mostly starts with depressive episode • Many depressives are hidden bipolars • Annual rate of diagnostic change from depression to hypomania – 1% • Length of episode of mania – 4 – 6 months • Episodic- relapsing and remitting
  35. 35. Course
  36. 36. Course • Inter-episodic duration shortens over time • Progressive shortening of cycle length • Average of 10 episodes over life time (2xMDD) • Residual symptoms predict poor prognosis • Lifetime risk of suicide – 15 times general pop • Lithium is antisuicidal • Bipolar II – rapid cycling
  37. 37. Risk of relapse
  38. 38. NICE Guidelines 2006
  39. 39. Treatment • Acute phase • Maintenance phase
  40. 40. Treat the acute phase Consider an antipsychotic if: • manic symptoms are severe • there is marked behavioural disturbance Consider valproate or lithium if: • there has been previous response and good compliance with one of these drugs Consider lithium if: • symptoms are less severe
  41. 41. Initiate long-term pharmacological treatment After a manic episode with significant risk and adverse consequences Bipolar I: two or more acute episodes Bipolar II: evidence of significant functional impairment or risk of suicide or frequently recurring episodes
  42. 42. Choose long-term drugs Base choice of lithium, olanzapine or valproate* on: • previous response • risk and precipitants of manic versus depressive relapse • physical risk factors • patient preference and history of adherence • cognitive state assessment if appropriate * Valproate should not be prescribed routinely for women of child-bearing potential
  43. 43. Try alternatives if needed If continuing symptoms or relapse, use alternative monotherapy or add second prophylactic agent: • lithium and valproate • olanzapine and lithium • valproate and olanzapine If this proves ineffective: • consult, or refer to, an expert in pharmacological treatment of bipolar disorder • prescribe lamotrigine or carbamazepine
  44. 44. Support long-term pharmacological treatment Ensure prescribing advisers are aware of NICE guidance, and what to consider when choosing treatment Focus on optimising appropriate long-term treatment Support service user education and empowerment in pharmacological treatment and management decisions Make use of early intervention teams, regional mental health trusts and CAMHS teams
  45. 45. Modify treatment for rapid cycling For an acute episode base treatment on that for manic and depressive episodes and: • review previous treatments; if inadequately delivered or adhered to, consider a further trial of previous treatments • optimise long-term treatment; each trial of medication should usually last at least 6 months • encourage patients to keep a mood diary
  46. 46. Use antidepressants with care Acute manic phase Stop antidepressants at onset of acute manic phase and decide if discontinuation is abrupt or gradual based on: • current clinical need • previous experience of discontinuation/withdrawal symptoms • the risk of discontinuation/withdrawal symptoms
  47. 47. Consider need for treatment Is long-term antidepressant treatment needed after an acute depressive episode? No evidence for reduced relapse rates May be associated with increased risk of mania
  48. 48. Educate staff and service users Raise awareness of effective antidepressant prescribing Highlight the importance of a thorough review of pharmacological history Support patient fears about antidepressant withdrawal Review prescribing policies and formularies, update as appropriate
  49. 49. Consider psychological therapy For those who are stable, individual structured psychological therapy should include: • at least 16 sessions over 6 to 9 months • psychoeducation • promotion of medication adherence • monitoring of mood, detection of early warnings and prevention strategies • coping strategies
  50. 50. Implement psychological therapy Offer individual structured psychological therapy Identify key people to support mood monitoring and coping strategies Identify training needs Review access to services Work collaboratively and engage the client, family or carers
  51. 51. Take possible pregnancy into account Valproate should not be used routinely for women who may become pregnant. It may: • cause foetal abnormalities • affect the child’s cognitive development If prescribed, ensure adequate contraception. Explain risks during pregnancy and to the health of the unborn child An antipsychotic may be used with caution
  52. 52. Provide care for women of child-bearing potential Review care pathways and management of bipolar disorder in women of child-bearing potential Raise awareness of the effects of bipolar disorder and treatment on: • conception • pregnancy • child Engage with patients, discuss contraception and family planning
  53. 53. Mitigate drug-related weight gain Review medication strategy and consider: • dietary advice and support • advising regular increased aerobic exercise • referring to a specialist mental health diet clinic or health delivery group • referring to a dietitian if needed for people with complex comorbidities
  54. 54. Support patients in controlling weight Review risk of weight gain when prescribing, offer early dietary advice and support Offer diet clinics or health delivery groups locally Identify a named key worker with appropriate training, use the care programme approach (CPA) Document in clinical notes/individualised care plan
  55. 55. Review annually Over the course of the year an annual review should include: • lipid levels, including cholesterol, in patients over 40 • plasma glucose levels • weight • smoking status and alcohol use • blood pressure
  56. 56. Establish review systems Agree responsibility locally Establish monitoring and early warning systems Develop systems for responsibility and intervention Communicate results Follow up non attendance
  57. 57. Lithium – Gold standard
  58. 58. Efficacy of lithium – all relapse Geddes J, Burgess S, Hawton K, Jamison K, Goodwin G. American Journal of Psychiatry 2004 217-222
  59. 59. Efficacy of lithium – Mania Geddes J, Burgess S, Hawton K, Jamison K, Goodwin G. American Journal of Psychiatry 2004 217-222
  60. 60. Efficacy of Lithium – Depression? Geddes J, Burgess S, Hawton K, Jamison K, Goodwin G. American Journal of Psychiatry 2004 217-222
  61. 61. Lithium - summary • Mania – Acute treatment – Strong evidence in the treatment of moderate to severe manic episodes. • Depression – Acute treatment – Controversial, but recognized as a therapeutic option. • Maintenance therapy – lithium prevents relapse and recurrence in in bipolar I disorder patients with recent manic or hypomanic episodes. – More effective in preventing episodes of the manic/hypomanic type, including mixed episodes, than preventing depressive episodes. – In rapid cycling patients – useful in acute phase but is not likely to prevent recurrences. – Reduces the high suicide rates associated with mood disorders.
  62. 62. Lithium – Responder signature • Essential features – Recurrent mood disorder – Episodic course of illness – Remission is complete between episodes • Indicative features – Predominance of depressive episodes ! – Absence of rapid cycling pattern – Episodic course in another family member – No significant psychiatric comorbidity – Classic pattern of mood episodes
  63. 63. Metabolic effects of Lithium Lithium: a review of its metabolic adverse effects Callum Livingstone and Hagen Rampes Journal of Psychopharmacology, May 2006; vol. 20: pp. 347 - 355.
  64. 64. Monitoring – Lithium (ISBD) • Baseline – Thyroid stimulating hormone – Serum calcium • Serum levels – Trough levels at steady state (> 5 days) on initiation of therapy, until two consecutivelevels within the therapeutic range are established for the same dosage – At steady state after dose changes – Every 3–6 months and as clinically indicated at stable dosages for theduration of treatment • Longitudinal – Urea and creatinine every 3–6 months for the duration of treatment – Serum calcium, thyroid stimulating hormone, and weight at 6 months, then annually Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, Beaulieu S, Yatham LN, Berk M. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009: 11: 559–595.
  65. 65. Anticonvulsants - MS • Valproate, (divalproex) – strong evidence - effectiveness in mania, – moderately strong evidence - benefits in prophylaxis of recovered states – recent proof-of-concept evidence for benefits in bipolar depression. • Lamotrigine has – strong evidence for evidence in maintenance treatment of bipolar depression – Lamotrigine - ineffective in mania and has lacked efficacy in acute bipolar depression • Carbamazepine – Strong evidence for effectiveness in mania, – lacks adequate studies in other aspects of bipolar disorder treatment. – Adverse effects and inducer
  66. 66. Monitoring – Anticonvulsants (ISBD) • Baseline – Valproate and carbamazepine: check for history of haematological or hepatic disease • Serum levels n – Valproate and carbamazepine: 2 levels to establish therapeutic dose (separated by 4 weeks for carbamazepine), then as clinically indicated • Longitudinal n – Valproate a : weight, full blood count, liver function test and inquiry of menstrual changes (for women of reproductive age) every 3 months for the first year, then annually – Carbamazepine: monthly full blood count, liver function test, and electrolytes, urea, and creatinine for the first 3 months, then annually; review oral contraceptive efficacy – Carbamazepine and lamotrigine: remind patients to promptly withhold medications and seek medical attention within 24 h of emergence of dermatological eruptions – Valproate and carbamazepine: advice on bone health
  67. 67. Antipsychotics • Typical antipsychotics, – Haloperidol - clear evidence on the efficacy of on the treatment of acute mania. – Faster onset of action of haloperidol as compared to either lithium or atypical antipsychotics. – Risk of tardive dyskinesia, extrapyramidal side effects and a possible increased risk of non-adherence. • Atypical antipsychotics – has been demonstrated for aripiprazole, clozapine, olanzapine, quetiapine, risperidone and ziprasidone. – Limitations - risk of weight gain and dyslipidemia. – Comparison among different atypical antipsychotics agents are difficult to determine as there are no conclusive head to head studies. – There is also a paucity of studies comparing atypical antipsychotics with lithium.
  68. 68. Monitoring – Antipsychotics (ISBD) • Baseline – Inquire about personal or family history of cardiac problems, including congenital long QT syndrome • Longitudinal – Weight: monthly for the first 3 months, then measures every 3 months for the duration of treatment – Blood pressure and fasting glucose: every 3 months for the first year, then annually – Fasting lipid profile: at 3 months after initiating treatment, then annually – Electrocardiogram and prolactin levels where clinically indicated
  69. 69. First-line recommendations for acute bipolar depression Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Malhi, Gin; Adams, Danielle; Berk, Michael. Bipolar Disorders. 11 Sup 2:55-76, June 2009. Copyright © 2009 Blackwell Publishing Ltd. Published by Munksgaard International Publishers Ltd. 2
  70. 70. Bipolar depression Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Malhi, Gin; Adams, Danielle; Berk, Michael. Bipolar Disorders. 11 Sup 2:55-76, June 2009.
  71. 71. Bipolar depression • Partitioning treatment into acute and maintenance therapy is difficult based on the paucity of current evidence. • Lithium and lamotrigine - first-line treatment in preference to valproate. • For acute episodes, quetiapine and olanzapine equally efficacious • Antipsychotics – significant side effects – lack of both long-term research data • Lithium and the anticonvulsants – slower to effect symptomatic change Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Malhi, Gin; Adams, Danielle; Berk, Michael. Bipolar Disorders. 11 Sup 2:55-76, June 2009.
  72. 72. Efficacy of pharmacological agents as phase-specific treatments in bipolar disorder based on available evidence Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Malhi, Gin; Adams, Danielle; Berk, Michael. Bipolar Disorders. 11 Sup 2:55-76, June 2009. Copyright © 2009 Blackwell Publishing Ltd. Published by Munksgaard International Publishers Ltd. 2
  73. 73. Psychological therapies Lam DH, Burbeck R, Wright K, Pilling S. Psychological therapies in bipolar disorder: the effect of illness history on relapse prevention – a systematic review. Bipolar Disord 2009: 11: 474–482.
  74. 74. MCQ 1 The proportion of patients that develop a depressive episode and then go on to develop an episode of mania within 10 years is approximately a. 1 in 2 b. 1 in 10 c. 1 in 4 d. 1 in 50 e. 1 in 200
  75. 75. MCQ 1 • Ans B • In community studies, one in ten patients who begin with a depressive episode go on to develop an episode of mania within 10 years. If the illness begins at a younger age, the switch happens earlier. This rate increases to nearly 50% if severely depressed hospitalised patients are considered. Long term follow up studies blinded for severity and number of previous episodes show much lesser conversion rates (3.2%). It is known that the majority of bipolar patients, particularly women, begin with depressive episodes. Among hospitalised depressed patients followed up for nearly a decade 1% a year converted to bipolar I and 0.5% a year converted to bipolar II. However, this conversion rate is less for outpatients with depression. Factors associated with a change of polarity from unipolar to bipolar were younger age, male sex, family history of bipolarity, antidepressant induced hypomania, hypersomnic and retarded phenomenology, psychotic depression, and postpartum episode. The mean age at which the switch occurs is 32 years. The average number of previous episodes in those who switch varies between two and four. The huge differences in switch rates probably reflect the severity of the initial depression, the length of follow-up, and the expanding definitions of bipolar II disorder. • • Angst J, Sellaro R, Stassen HH, et al. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. Journal of Affective disorders 2005: 84;149-157 • Stein G & Wilkinson G., eds. Seminars in General Adult Psychiatry, 2nd edn. Gaskell, 2007, p. 18. •
  76. 76. MCQ 2 Which of the following is true with regard to longitudinal course of bipolar disorder? a. The duration of mood episodes decreases progressively b. Initial episodes have more rapid onset than the later episodes c. The interval between episodes decreases progressively d. Seasonal pattern is more common in bipolar type 1 than type 2 e. Later episodes are more likely to be triggered by life events than the initial episodes
  77. 77. MCQ 2 • Ans. C • In any patient with bipolar disorder, the duration of individual mood episodes tends to be relatively stable throughout the course, with mania lasting shorter than depression generally. But the onset may become more rapid with age. The interval from one episode to the next tends to decrease through the course of illness though some evidence suggests a tendency for the inter-episode intervals to stabilize after around five episodes. Patients with seasonal patterns are more commonly of bipolar II subtype than bipolar I. The first episode is more likely to be triggered by life events than later episodes. Ambelas confirmed the strong correlation between stressful life events and first manic admissions; this association weakens as the illness progresses. This is particularly true for younger bipolar patients with mania rather than depression. This is consistent with the hypothesis of kindling phenomenon in bipolar disorders. • Stein G & Wilkinson G., eds. Seminars in General Adult Psychiatry, 2nd edn. Gaskell, 2007, p. 27-29 • Ambelas A. Life events and mania: a special relationship? Br J Psychiatry 1987; 150: 235–240.
  78. 78. MCQ 3 Polyuria can be a troublesome side effect with lithium therapy. Which of the following is NOT correct with response to lithium related polyuria? a. It is seen in one –third of those treated with lithium b. It is usually reversible c. Once daily dose produces more polyuria than multiple doses a day d. Amiloride is an useful intervention e. Dose reduction may alleviate polyuria
  79. 79. MCQ 3 • Ans . C • Lithium related polyuria and polydipsia are seen in nearly one-third of those treated. Polyuria is usually reversible in early stages but may become obstinate with longer duration of therapy. When once daily preparation of lithium is used instead of multiple divided doses, the frequency of polyuria seems to be lesser; but a direct correlation between plasma peaks and polyuria is not clearly demonstrated in clinical samples. Dose reduction or use of amiloride can be tried in those who have troublesome levels of polyuria. Amiloride has relatively lesser propensity to cause electrolyte disturbances when co-prescribed with lithium compared to other diuretics. • Stein G & Wilkinson G., eds. Seminars in General Adult Psychiatry, 2nd edn. Gaskell, 2007, p. 34
  80. 80. MCQ 4 Compared to general population, the risk of Ebstein’s anomaly in children of mothers exposed to lithium during the first trimester of pregnancy is a. 2 – 3 times higher b. 10 – 20 times higher c. 50- 80 times higher d. 100 – 120 times higher e. 4 - 5 times higher
  81. 81. MCQ 4 • Ans : B • The risk of major congenital anomalies in children exposed to lithium in uterus is 4-12%. This is nearly 3 times higher than non-exposed foetuses. The UK National Teratology Information Service has concluded that lithium increases the risk of cardiac malformations of around eight-fold. First trimester exposure to lithium increases the risk of Ebstein’s anomaly by nearly 10-20 times, bringing the absolute risk to 0.05-0.1%. • Stein G & Wilkinson G., eds. Seminars in General Adult Psychiatry, 2nd edn. Gaskell, 2007, p. 36 • Williams, K & Oke, S. Lithium and pregnancy. Psychiatric Bulletin , 2000: 24; 229-231
  82. 82. MCQ 5 1. Which of the following predicts good prophylactic effect of lithium in bipolar disorder? a. Absence of family history of bipolar disorder b. Presence of neurological signs c. ‘Depression- Mania-well interval’ pattern of bipolar course d. Good antimanic efficacy during acute episode e. Absence of complete inter-episode recovery
  83. 83. MCQ 5 • Ans: D • Various clinical, biological and genetic factors that predict lithium responsiveness in prophylaxis of bipolar disorder have been studied. Presence of typical features of bipolar disorder, good inter-episode clinical recovery, family history of bipolar disorder, having mania as first bipolar episode, good response to lithium in acute manic phase predict lithium responsiveness. Presence of neurological signs, comorbid substance use and presence of rapid cycling predict poor response to lithium. Lithium response in a sample composed of relatives of lithium-responder probands was 67% compared to 30% in comparison group; this indicates that lithium responsiveness may have certain degree of heritability. • Stein G & Wilkinson G., eds. Seminars in General Adult Psychiatry, 2nd edn. Gaskell, 2007, p. 40 • Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942-947
  84. 84. Further reading – Goodwin and Jamison’s book – Bipolar disorders journal (2009 Suppliment) – New Oxford Textbook of Psychiatry – MCQs – Palaniyappan, Krishnadas Best of 5 MCQs for MRCPsych Paper 1,2 and 3
  85. 85. Fin

×